Breadcrumb Home Business Activities Lundbeckfonden BioCapital Lundbeckfonden BioCapital Portfolio Spero Therapeutics Spero Therapeutics Spero has a pipeline of novel treatments for multi-drug resistant (MDR) bacterial infections. Two programs are in clinical phase I Related news about Spero Therapeutics Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr Spero Therapeutics website Lundbeckfonden BioCapital Invested 2015 IPO in 2017 – SPRO (Nasdaq) Location Boston, Massachusetts, USA